Business Wire

PERSONETICS

31.1.2023 08:01:43 CET | Business Wire | Press release

Share
European banks say that traditional money management tools are not meeting expectations

Personetics, the global leader in financial data-driven customer engagement for financial services today released a report titled Spotlight On Europe: Banks Need To Nurture Customers’ Financial Well-Being. The report, based on a study conducted by Forrester Consulting on behalf of Personetics, details the opportunities and challenges associated with leveraging money management tools to enhance customer engagement and increase lifetime value.

“Now more than ever, customers demand greater control of their finances and expect their banks to deliver real-time, financial data-driven personalised advice and long-term planning,” said Dorel Blitz, VP of Strategy & Business Development at Personetics. “Yet Forrester’s report reveals that existing Personal Financial Management (PFM) tools are neither meeting customer expectations nor delivering business impact for banks. The banks that will thrive are those which will take advantage of the opportunity to provide advanced and proven money management capabilities.”

Forrester based its conclusions on responses from key banking decision-makers. The report shows that while most banks offer basic PFM and money management capabilities there is a growing, urgent need for both banks and their customers to “evolve their approach in order to successfully raise customers’ levels of financial well-being.”

For example, the European survey revealed disappointingly low levels of customer adoption and engagement with digital money management tools. Although nearly three-quarters (73%) of bankers say they already offers customers some sort of digital money management tool, 77% state that fewer than half of their customers actively use these tools.

The report found that adoption is low because existing money management tools fail to deliver tangible outcomes for customers. Today’s money management tools follow a one-size-fits-all approach, meaning they put too much onus on the end user and fail to help customers achieve their financial goals.

Mr. Blitz added: “The good news is that banks are alive to the issues they face. Now it’s a matter of finding the right path forward, through proactive, hyper-personalised solutions at scale that can make a difference today.”

Below are the core findings across Europe.

Banks have high expectations for money management solutions.

When asked about the benefits of implementing digital technologies for this purpose, the top three benefits were increased customer engagement (47%), increased revenue through upsell and cross-sell (43%) and new customer acquisition (43%).

Traditional PFM fails to deliver effective customer outcomes.

One of the main challenges in deploying these digital capabilities is the absence of an enterprise-wide approach to enhancing customer outcomes. Just over half of banks say they can provide sufficient personalised financial insights and advice based on customers’ financial data. This leaves a significant number of banks without the means to deliver competitive and appealing offers and products for their customers.

A major opportunity exists for innovative banks.

Banks should use an advanced money management platform to deliver business impact, increase revenue, profitability, and customer lifetime value. To do this, financial institutions need to partner with the right vendor and invest in advanced capabilities, adopt a financial data-driven approach, and deliver solutions that customers need when they need them.

Read the full report here.

About Personetics

Personetics is a global financial data-driven personalised customer engagement platform for financial services. The company’s mission is to shape the future of “Self-Driving Finance,” where financial institutions can proactively help consumers improve their financial well-being and achieve financial goals.

Personetics serves more than 100 financial institutions in 32 global markets and reaches 140 million customers. The company is backed by leading venture capital and private equity investors, with offices in New York, London, Tel Aviv, Singapore, Tokyo, Paris, Spain, and Australia.

Learn more at personetics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230130005691/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release

Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release

Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly

SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release

The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter

Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release

Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant

Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye